Phase 2 Endometrial Cancer Trial, Recruiting NCT06462378 Sponsor: University of Aarhus Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT06462378
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have cervical cancer that doctors believe can be treated with the goal of curing it, using radiation therapy (with or without chemotherapy), including a specialised type of internal radiation
  • Your biopsy has confirmed one of three specific types of cervical cancer: squamous cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma
  • Your cancer has been formally staged using standard international guidelines
  • Your cancer has spread to nearby pelvic lymph nodes (at least 3) or to lymph nodes near the large blood vessels in your abdomen, but not to distant parts of the body (confirm with trial site)
  • Some spread to lymph nodes in the upper abdominal area (below a specific spinal level called L1-L2) is allowed
  • You have had specific scans — an MRI and a PET-CT scan — of your abdomen and the area around your spine at the time of diagnosis
  • You are 18 years of age or older
  • You are able to understand Danish or Swedish
  • You have given your written agreement to take part in the trial

Who may not be able to join:

  • You have or have had another type of cancer (exceptions may be made for very early-stage cervical changes or a common type of skin cancer — confirm with trial site)
  • Your cancer has spread to areas of the body beyond the upper abdominal lymph node region described above
  • You have previously had radiation therapy to your pelvis or abdomen
  • Your treatment plan combines radiation with surgery beforehand
  • You are receiving chemotherapy before the main treatment (called neoadjuvant chemotherapy)
  • You have a medical reason why you cannot have an MRI scan
  • You have a medical reason why you cannot have the internal radiation treatment used in this trial
  • You have a medical reason why you cannot have proton therapy
  • Your cancer is a specific rare type called small cell or neuroendocrine tumour
  • You have an active serious infection or a severe health condition that could prevent you from completing treatment
  • You are pregnant, breastfeeding, or able to become pregnant without using adequate contraception
  • You are living with HIV
  • There is no way for the trial team to follow up with you after treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hanne Matthiesen, MD, PhD, Department of Oncology, Capital Region Denmark

Phone: 004592432356

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
20 May 2024
Est. completion
20 May 2029

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Acute Bone marrow toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov